VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)--Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma (“Alera or Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark Office (USPTO) of U.S.

不列颠哥伦比亚省温哥华和佛罗里达州斯图亚特市——（商业新闻短讯）——Lobe Sciences，Ltd.（“Lobe Sciences”或“公司”）（CSE:Lobe），（OTCQB:LOBEF）和Alera Pharma（“Alera或Alera Pharma”），生物制药公司专注于开发治疗严重未满足医疗需求的疾病的产品，今天宣布美国专利商标局（USPTO）发布。

Patent number 12,102,616 titled “Psilocin Mucate”. As previously announced, Lobe Sciences will assign the intellectual property rights associated with this patent to Alera Pharma..

专利号12102616，标题为“Psilocin Mucate”。如前所述，Lobe Sciences将把与该专利相关的知识产权转让给Alera Pharma。。

This newly issued patent contains claims covering compositions of matter, methods of use and methods of production for psilocin mucate. Subject to payment of patent maintenance fees in the third, seventh and eleventh years following the grant, the patent will be valid until expiration in July, 2043.

这项新发布的专利包含涵盖裸盖菇素粘液的物质组成，使用方法和生产方法的权利要求。在授予后第三年、第七年和第十一年支付专利维护费的情况下，该专利将有效至2043年7月到期。

The Company has also filed several additional patent applications with the intention of broadening the base of claims. In addition to filings with the USPTO, the Company has filed for international coverage of its intellectual property..

该公司还提出了几项额外的专利申请，旨在扩大权利要求的基础。除了向USPTO提交申请外，该公司还申请了其知识产权的国际覆盖范围。。

Mr. Rick Goulburn, CEO of Alera Pharma, Inc. stated, “We are excited to receive this foundational and broad patent on Conjugated Psilocin™ which recognizes the unique properties of this psilocin analogue invention. Psilocin alone is a very unstable molecule that to date, has not successfully been developed as an oral stable prescription medicine.

Alera Pharma，Inc.首席执行官Rick Goulburn先生表示：“我们很高兴收到这项关于共轭Psilocin™的基础性和广泛的专利，该专利认可了这种Psilocin类似物发明的独特特性。单独的Psilocin是一种非常不稳定的分子，迄今为止，尚未成功开发为口服稳定处方药。

Companies trying to develop treatments have had to rely on using the prodrug psilocybin which relies on conversion in the gut resulting in poor bioavailability, uptake, and related adverse effects. With Conjugated Psilocin™, we now have a stable, orally available psilocin that is rapidly and fully bioavailable.

试图开发治疗方法的公司不得不依赖于使用前药psilocybin，它依赖于肠道中的转化，导致生物利用度差，摄取和相关的不良反应。使用缀合的Psilocin™，我们现在可以快速且完全生物利用稳定的口服Psilocin。

As a result, we believe that we can create an oral prescription medication that can be precisely dosed and developed for a variety of neurological disorders.”.

因此，我们相信我们可以创造一种口服处方药，可以精确给药并开发用于各种神经系统疾病。”。

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences also commented, “We are excited that this patent has issued and validated the unique opportunity to develop an oral and stable psilocin product. We are highly aware of the desperate need patients with Chronic Cluster Headache have for this medication and we are anxious to move this product through the FDA approval process as quickly and efficiently as possible.

Lobe Sciences董事长兼首席执行官弗雷德·桑西利奥博士（Fred Sancilio）也评论道：“我们很高兴这项专利为开发口服稳定的psilocin产品提供了独特的机会。我们高度意识到慢性丛集性头痛患者对这种药物的迫切需求，我们渴望尽快有效地通过FDA的批准程序。

However, treating Chronic Cluster Headaches is not our final application of this new and exciting drug candidate, and its potential use to treat several other disorders that are currently being studied in clinical trials utilizing psilocybin are clearly on our radar.”.

然而，治疗慢性丛集性头痛并不是我们对这种新的令人兴奋的候选药物的最终应用，它可能用于治疗目前正在利用裸盖菇素进行临床试验研究的其他几种疾病，这显然是我们关注的。”。

About Conjugated Psilocin™

关于共轭Psilocin™

Conjugated Psilocin™ is a novel, oral, stable analogue of psilocin, the active metabolite of the prodrug psilocybin. Psilocybin is a psychedelic compound that has been identified as having therapeutic potential in a variety of neurological conditions. Psilocybin is dephosphorylated to the active moiety psilocin with poor bioavailability and pharmacokinetics.

缀合的Psilocin™是Psilocin（前药psilocybin的活性代谢产物）的新型口服稳定类似物。psilocybin是一种迷幻化合物，已被确定在多种神经系统疾病中具有治疗潜力。裸盖菇素被去磷酸化为活性部分裸盖菇素，生物利用度和药代动力学较差。

Psilocin itself is a very unstable compound that has been difficult to develop as a pharmaceutical medicine. Conjugated Psilocin™ is a stable, highly bioavailable pharmaceutical ingredient with the potential to be developed as a prescription medicine in a variety of neurological disorders..

裸盖菇素本身是一种非常不稳定的化合物，很难作为药物开发。缀合的Psilocin™是一种稳定的，高度生物利用的药物成分，有可能被开发为各种神经系统疾病的处方药。。

About Lobe Sciences Ltd.

关于Lobe Sciences Ltd。

Lobe Sciences, Ltd. is a commercial stage biotechnology company focused on developing transformative therapies for unmet medical needs. Through its subsidiaries, Alera Pharma, Inc. and Altemia, Inc., Lobe Sciences is developing patented drug candidates to treat chronic cluster headache (Alera) and innovative medical foods to address deficiencies commonly seen in sickle cell disease (Altemia).

Lobe Sciences，Ltd.是一家商业阶段的生物技术公司，专注于为未满足的医疗需求开发变革疗法。通过其子公司Alera Pharma，Inc.和Altemia，Inc.，Lobe Sciences正在开发专利候选药物，用于治疗慢性丛集性头痛（Alera）和创新医疗食品，以解决镰状细胞病（Altemia）常见的缺陷。

Lobe Sciences provides common services to its subsidiaries including accounting, finance, and general administrative services..

Lobe Sciences为其子公司提供公共服务，包括会计、财务和一般行政服务。。

About Alera Pharma, Inc.

关于Alera Pharma，Inc。

Alera Pharma, Inc. is a private subsidiary of Lobe Sciences, Ltd., dedicated to the development and commercialization of innovative pharmaceutical products. With a focus on addressing unmet medical needs, Alera Pharma is committed to improving patient outcomes in a variety of neurological disorders through cutting-edge research and development..

Alera Pharma，Inc.是Lobe Sciences，Ltd.的私人子公司，致力于创新药物产品的开发和商业化。Alera Pharma专注于解决未满足的医疗需求，致力于通过尖端研究和开发改善各种神经系统疾病的患者预后。。

Cautionary Statement Regarding 'Forward-Looking' Information

关于“前瞻性”信息的警告声明

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the belief that the Company and Alera will be able to create an oral prescription medication that can be precisely dosed and developed for a variety of neurological disorders; the belief that patients with Chronic Cluster Headache have a need for Conjugated Psilocin™; the anticipated approval by the FDA, and the timing thereof; and the Company’s belief that psilocybin may be able to treat several other disorders, are forward-looking statements and contain forward-looking information.

本新闻稿包括某些可能构成适用加拿大证券法意义上的前瞻性信息的声明和信息。本新闻稿中的所有声明，除历史事实声明外，包括关于未来估计、计划、目标、时间安排、假设或未来表现预期的声明，包括但不限于：相信公司和Alera将能够创造一种口服处方药，可以精确给药和开发用于各种神经系统疾病；认为慢性丛集性头痛患者需要结合的Psilocin™；FDA的预期批准及其时间安排；该公司相信裸盖菇素可能能够治疗其他几种疾病，这是前瞻性的陈述，并包含前瞻性信息。

Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur..

一般来说，前瞻性陈述和信息可以通过使用前瞻性术语来识别，例如“意图”或“预期”，或者这些词语和短语的变体，或者某些行动、事件或结果“可能”、“可能”、“应该”或“将要”或发生的陈述。。

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: any prescription medication that is developed from Conjugated Psilocin™ can be precisely dosed and developed for a variety of neurological disorders; that there is a need for need for Conjugated Psilocin™; the Company will obtain FDA approval for Conjugated Psilocin™ and will be able to do so on an expedited timeline; and Conjugated Psilocin™ may have use in treatment of other disorders.

前瞻性声明基于公司做出的某些重大假设和分析，以及截至本新闻稿发布之日管理层的意见和估计，其中包括：任何由共轭Psilocin™开发的处方药都可以精确给药并开发用于各种神经系统疾病；需要共轭的Psilocin™；该公司将获得FDA对共轭Psilocin™的批准，并将能够尽快完成；缀合的Psilocin™可用于治疗其他疾病。

These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

这些前瞻性陈述受到已知和未知风险、不确定性和其他因素的影响，这些风险、不确定性和其他因素可能导致公司的实际结果、活动水平、业绩或成就与此类前瞻性陈述或前瞻性信息所明示或暗示的结果、活动水平、业绩或成就存在重大差异。

Important risks that may cause actual results to vary, include, without limitation, the risk that: Conjugated Psilocin™ cannot be developed into a precisely dosed prescription medication; the need for Conjugated Psilocin™ is less significant than the Company and Alera anticipate; the Company will not obtain FDA approval for Conjugated Psilocin™ or will not be able to do so on the timeline anticipated; and Conjugated Psilocin™ will not have application in treatment of other disorders..

；对共轭Psilocin™的需求不如公司和Alera预期的那么重要；该公司将无法获得FDA对共轭Psilocin™的批准，或者无法在预期的时间表内获得批准；并且缀合的Psilocin™将不适用于治疗其他疾病。。

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

虽然公司管理层试图确定可能导致实际结果与前瞻性声明或前瞻性信息中所含结果产生重大差异的重要因素，但可能还有其他因素导致结果不符合预期、估计或预期。

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

由于实际结果和未来事件可能与此类报表中预期的结果和事件存在重大差异，因此无法保证此类报表将被证明是准确的。因此，读者不应过度依赖前瞻性陈述和前瞻性信息。读者应注意，依赖此类信息可能不适合用于其他目的。

The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws..

公司不承诺更新通过引用纳入本文的任何前瞻性声明、前瞻性信息或财务展望，除非符合适用的证券法。。